Pre Diabetes
Conditions
Keywords
Eriocitrin, Citrus bioflavonoids, Flavanone, Pre-diabetes, Blood glucose
Brief summary
Supplementation with citrus bioflavonoids (hesperidin, naringin, diosmin and eriocitrin, among others) has been associated with an improvement in the glycidic and lipid profile, reduction of insulin resistance and systemic inflammation, and reduction of endothelial damage. This study aims to evaluate the effects of eriocitrin supplementation on the metabolic parameters of pre-diabetic individuals. Participants will be adults with pre-diabetes who will receive 200 mg / d of eriocitrin. Before, during and after treatment, anthropometric measures (weight, body composition and circumferences), biochemical (lipid and glucose profile, inflammatory parameters, endothelial markers, liver function, renal function) will be evaluated. Metabolic parameters that constitute risk factors for diabetes and associated chronic diseases are expected to be improved by supplementation with eriocitrin.
Detailed description
Individuals aged 35-60 years and who present at least one of the following criteria: (1) increased fasting blood glucose from 6.1 to 7.0 mmol / L, (2) decreased glucose tolerance of 7 , 8 to 11.1 mmol / L, and (3) glycated hemoglobin with values between 5.7 and 6.4% 10 will be eligible to participate in this study. The exclusion criteria will be to use hypoglycemic, hypolipidemic drugs, dietary supplements (vitamins, minerals, bioflavonoids, prebiotics, probiotics or other bioactive compounds), exercise intensely (more than 10 hours per week), history of cardiovascular diseases , diabetes mellitus, liver and kidney disease. The selected individuals will be distributed randomly in 2 groups through random number generator program. Group A (n = 20) will receive 200 mg / d of eriocitrin for 12 weeks, with washout for 2 weeks and then receive 200 mg / d of placebo for 12 weeks; group B (n = 20) will receive 200 mg / d placebo for 12 weeks with washout for 2 weeks and then receive 200 mg / d placebo for 12 weeks. The primary endpoint will be fasting blood glucose, blood glucose 2 hours after oral glucose tolerance test (GTTO), and HbA1c. The secondary endpoint will be insulin, HOMA-IR, total cholesterol, triglycerides, HDL-cholesterol, LDL-cholesterol, ALP, yGT, AST, ALT, TNF-α, IL-6, CRP, body weight, body mass index BMI), muscle mass, fat mass, body fat and waist-hip ratio, and macronutrient intake.
Interventions
DIETARY_SUPPLEMENTEriocitrin
A crossover, double-blind, randomized, placebo-controlled clinical study with a duration of 26 weeks will be performed. All individuals and the principal investigator will remain blind to treatment until all analyzes are completed. Participants will be invited to attend 12-hour fasting to measure glucose levels, glycated hemoglobin and to perform the glucose tolerance test, in addition to an individual interview (Appendix B) to confirm eligibility according to the inclusion and exclusion criteria . The collection of blood and the glycemic curves will be performed at the beginning of the first, 12th, 14th and 26th week in the Laboratory of Clinical Analyzes ( Araraquara) At the beginning of the first, 12th, 14th and 26th week the following anthropometric parameters will be evaluated: body weight (kg), muscle mass (kg), fat mass (kg), body fat (%) (InBody 720, Biospace, Tokyo, Japan ) and waist-hip ratio.
Sponsors
São Paulo State University
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
35 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* 35-60 years * Increased fasting blood glucose from 6.1 to 7.0 mmol / L or, * Decreased glucose tolerance of 7 , 8 to 11.1 mmol / L or, * Glycated hemoglobin with values between 5.7 and 6.4%
Exclusion criteria
* Use hypoglycemic, hypolipidemic drugs, * Use dietary supplements (vitamins, minerals, bioflavonoids, prebiotics, probiotics or other bioactive compounds), * Exercise intensely (more than 10 hours per week) * History of cardiovascular diseases , diabetes mellitus, liver and kidney disease.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Fasting glycemia | 0-12-18-26 week | Changes in serum glycemia concentration before and after administration of the intervention/placebo |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of change in plasma glucose concentration | 0-12-18-26 week | Changes in serum 2 hours after oral glucose tolerance test (mg/dL) before and after administration of the intervention / placebo |
| Rate of change in plasma HbA1c | 0-12-18-26 week | Changes in serum HbA1c (%) before and after administration of the intervention / placebo |
| Rate of change in plasma lipid concentration | 0-12-18-26 week | Changes in serum cholesterol (mg/dL), triglycerides (mg/dL),HDL-C(mg/dL), LDL-C(mg/dL) before and after administration of the intervention/placebo |
| Rate of change in plasma insulin concentration | 0-12-18-26 week | Changes in serum insulin (µU/mL) before and after administration of the intervention / placebo |
| Rate of change in plasma inflammatory parameters | 0-12-18-26 week | Changes in CRP (mg/dL), TNF-a (mg/dL), IL-6 (mg/dL) before and after administration of the intervention / placebo |
| Rate of change in anthropometric parameters | 0-12-18-26 week | Changes in body weight (Kg), muscle mass (Kg), fat mass (Kg) before and after administration of the intervention / placebo |
| Rate of change in plasma hepatic enzymes | 0-12-18-26 week | Changes in ALT (U/L), AST (U/L), ALP (U/L), GGT (U/L) before and after administration of the intervention / placebo |
Countries
Brazil
Outcome results
None listed